

MINUTES
UTAH
CONTROLLED SUBSTANCES ADVISORY COMMITTEE
MEETING

November 12, 2013 – 4:00 p.m.

North Conference Room 1st Floor
Heber M. Wells Building
Salt Lake City, UT 84111

CONVENED: 4:05 p.m.

ADJOURNED: 5:35 p.m.

Bureau Manager:

Debra Hobbins, DNP, APRN

Board Secretary:

Boyce Barnes

Committee Members Present:

David N. Sundwall, MD, Chairperson
Elizabeth Howell, MD
Darin M. Vercillo, MD
Jeffrey Paul Clark, MD
Glen R Hanson, Ph.D, DDS (by telephone)
David Young, Pharm D
Deputy Commissioner Jeff Carr

Committee Members Excused:

Kenneth Schaecher, MD
Blaine Winters, APRN
Todd C. Grey, MD
Scott W. Reed, AAG
Jeffrey Wright, ND

Guests:

Representative Gage Froerer
Representative Brian Greene
Jennifer McNair, Bureau of Forensic Services
Patrice Grossman
Natassja Grossman
Justina Tanner
Keri Beardall
Samantha Beardall
Rebecca Hyer
Kris Hansen, Epilepsy Association of Utah
Candi Huff
Jason Huff
Jayne Richards
Eric Kohler
Barbara Kohler
Grant Holmes
Chris Stock

Cassandra Clement
Tifanee Anderson
Kim Phillips
Brandi Laco
Jennifer Macfarlane
April McClellan
Chad McClellan
Dan Bayler
Tiffany Milne, Utah Council for Crime Prevention
Emilie Campbell, Hope 4 Children with Epilepsy
April Sintz
Seasan Atwater
Clinton Atwater
Julie Christensen, Hope 4 Children with Epilepsy
Daina Swapp, Hope 4 Children with Epilepsy
Jason Swapp, Hope 4 Children with Epilepsy
Kylie Swapp, Hope 4 Children with Epilepsy
Mandi Cromar, Hope 4 Children with Epilepsy
David Cromar, Hope 4 Children with Epilepsy
Amie Larsen, Hope 4 Children with Epilepsy
Bryan Larsen, Hope 4 Children with Epilepsy
Lindsey Addams, Hope 4 Children with Epilepsy
Holly Ferrin, Epilepsy Association of Utah
Annette Maughan, EAU/H4CE
Kwang Park
Connor Boyack, Libertas Institute
Brad Nelson, Hope 4 Children with Epilepsy
Katie Nelson, Hope 4 Children with Epilepsy
Ron Gordon, UJJ
Lela Weinet, Hope 4 Children with Epilepsy
Kyle Sintz, Hope 4 Children with Epilepsy
Cameron May, Hope 4 Children with Epilepsy
Laura Ulrich, Hope 4 Children with Epilepsy
Mark Ulrich, Hope 4 Children with Epilepsy
Rob Timmerman, Utah Prevention Coalition Association
Susan Wiet, MD
Kris Faunule
Mary Lou Emerson, USAAU Council

TOPICS FOR DISCUSSION

ADMINISTRATIVE BUSINESS:
September 9, 2013 Minutes:

DECISIONS AND RECOMMENDATIONS

Dr. Vercillo made a motion to approve the September 9, 2013 minutes as written. Dr. Howell seconded the motion. All Board members voted in favor of the motion.

Presentation and discussion regarding THC
for medical use:

Representative Froerer met with the Committee to discuss a THC product, Alepsia. Rep. Froerer indicated this product has been proven effective in epileptic children. Rep. Froerer introduced the Stanley Brothers from Colorado who developed the variety of hemp product which will be discussed. Rep. Froerer requested the Committee listen to the presentation and then provide input regarding the benefits, the disadvantages, and the potential long-term ramifications of this product and how it can best be utilized by the citizens of our state.

Mr. Josh Stanley discussed a special strain of non-psychoactive hemp that was developed. He indicated Alepsia was developed from an industrial hemp-quality hybrid cannabis plant and processed into an oil. Mr. Stanley indicated they began treatment in 2012 for a child with Dravet Syndrome. This patient was at the end of treatment and her parents were told by her doctors to prepare for her to die. The child has now been seizure-free after eighteen months of treatment with Alepsia.

Mr. Josh Stanley stated that because of the low percentage of THC (0.3%), he considers this substance (CBD) already legal in Utah. Utah laws allow importation of hemp, through food products, clothing, oils, and hand creams, etc. The difference between these products and Alepsia is the compound. He stated they use an ethanol extraction and that the extraction is suspended in olive oil. The oil extract is high in cannabidiol (CBD) but low in tetrahydrocannabinol (THC) making it non-psychoactive, according to Mr. Stanley. He stated that their lab follows USP standards. Mr. Stanley stated he feels that this is not a commerce issue, but a health issue. He indicated he is not asking to change Utah laws, but to allow his product to be available to families of epileptic children. He stated he sees no merit in families uprooting their lives by moving to Colorado. Mr. Stanley stated they have established a safety profile and there are apparent medicinal benefits. He indicated they are compliant with all Colorado regulations.

Mr. Stanley stated that *Realm of Caring* is a not-for-profit company. It has client support, client information, data collection, etc. The company provides discounted/free

Alepsia (5 cents per milligram per dose or \$175.00 per month).

Jennifer May, mother of a child with epilepsy, indicated that she is here representing 30-35 families with children with severe epilepsy. Ms. May indicated her child has tried over 25 treatments and those treatments did not work or are no longer effective. She indicated she has not left the state because her family respects the law, the community, and the doctors. She indicated they are waiting to be able to give the medication legally and want to comply with the laws of the state in order to give Alepsia to their children. Most of their children are disabled and she indicated they have tried everything. She indicated they are not extreme naturalists; they just want to take care of their children. If they lived in Colorado they could obtain treatment, but they would actually have to move there and become citizens of that state in order for their children to receive Alepsia treatment. Ms. May stated she would like to remain in Utah and find an answer to her problem.

Rep. Froerer stated Utah looks at health issues seriously and is often progressive. He stated that these families want to be able to use the product without breaking the law. Rep. Froerer stated this presentation was very informative and provocative and he hopes to find a solution.

Dr. Sundwall stated that the Controlled Substance Advisory Committee's role is to recommend changes to the Legislature and to recommend if a substance needs to be scheduled. Committee members questioned what would be needed to use this substance in Utah and what are the barriers.

Mr. Stanley stated they would like the Committee's acknowledgement that this substance is legal and meets the law. The federal law does not allow states to bring hemp into the state through interstate commerce. They stated that similar products that come in from other countries are legal but have pesticides in them. However, Utah cannot import from Colorado.

Committee members indicated they have some concerns about the unknown long-term side effects. Some strong

side effects of depression are known with the substance. The Committee would be in support of more research on this product in Utah.

Update:

State Crime Lab: Ms. McNair indicated she attended the National Alliance for Model State Drug Laws. She stated there were chemists, health professionals, and law enforcement individuals involved in the discussion of model synthetic substances/controlled substance analogue laws. Ms. McNair reported more states are using class definitions.

Utah Poison Control: A representative from Utah Poison Control indicated there is a worldwide trend for the use of the krokodile drug (desomorphine), which is the flesh-eating drug. However, there are no reported cases in Utah.

National trends and policies:

It was reported that Lortab is being moved from a Schedule III to a Schedule II controlled substance.

Next meeting:

The next meeting will be scheduled for January 14, 2014.

Note: These minutes are not intended to be a verbatim transcript but are intended to record the significant features of the business conducted in this meeting. Discussed items are not necessarily shown in the chronological order they occurred.

2/11/14

Date Approved



David N. Sundwall, Chairperson, Controlled Substances Advisory Committee

2/12/14

Date Approved



Debra Hobbins, Bureau Manager, Division of Occupational & Professional Licensing